EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Jonathan D Bender, Lauren Pommert, Lori R Backus, Andrea Bidwell, Courtney Blank, Erin H Breese, Karen C Burns, Adam Lane, Lynn H Lee, Benjamin Mizukawa, Robin E Norris, Maureen M O'Brien und 6 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70268 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Jonathan D Bender und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Daunorubicin, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jazz Pharmaceuticals, Cincinnati Children's Leukemia Research Fund, CancerFree KIDS Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML. Design/Methods In this first‐in‐pediatric, single center phase 1 study (NCT01943682), 27 patients with R/R acute leukemia (acute lymphoblastic leukemia [ALL, n = 3], AML [ n = 23], or mixed phenotype acute leukemia [MPAL, n = 1]) received one cycle of CPX‐351 (on days 1, 3, 5) at either 44 mg/m 2 daunorubicin/dose or 59 mg/m 2 daunorubicin/dose. The primary objectives were to determine the CPX‐351 recommended phase 2 dose (RP2D) and to evaluate its tolerability; secondary objectives were to assess marrow overall response rate (ORR) and cardiotoxicity.

Results

The RP2D was determined to be 44 mg/m 2 daunorubicin/dose. Grade ≥3 non‐hematologic toxicities occurred in 89% of patients including febrile neutropenia (85%), infection (52%), and maculo‐papular rash (37%). No grade ≥3 acute cardiac toxicities or significant changes in cardiac biomarkers were detected. The marrow ORR for AML patients was 48% (10/21 evaluable patients), despite high‐risk genetic findings in most and nearly half of patients having undergone prior hematopoietic stem cell transplant. No patients with ALL or MPAL responded.

Conclusion

CPX‐351 at 44 mg/m 2 daunorubicin/dose was safe and tolerable in children with R/R acute leukemia, showing promising activity in heavily pretreated, high‐risk AML and is now the FDA‐approved pediatric dose for therapy‐related AML or AML with myelodysplastic changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DaunorubicinLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsPrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasm Recurrence, LocalHumansChildFemaleCytarabineChild, PreschoolAdolescentMaleInfantPrognosisFollow-Up StudiesSurvival Rate

Stichwörter der Autor:innen

CPX‐351acute myeloid leukemiacardiotoxicityrelapsed leukemia

Substanzen

DaunorubicinCytarabineCPX-351

Autor:innen und Institutionen

  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Children's Hospital Colorado and the University of Colorado Cancer Center, Aurora, Colorado, USA.
  • Department of Pediatrics, Division of Pediatric Cardiology, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA.
  • Division of Cardiology, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Förderung

  • Jazz Pharmaceuticals, Cincinnati Children's Leukemia Research Fund
  • CancerFree KIDS Foundation

Zitieren

APA

Bender, J. D., Pommert, L., Backus, L. R., Bidwell, A., Blank, C., Breese, E. H., Burns, K. C., Lane, A., Lee, L. H., Mizukawa, B., Norris, R. E., O'Brien, M. M., Peck, D., Phillips, C., Ryan, T. D., Young, J., Absalon, M., & Perentesis, J. P. (2026). CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70268

Vancouver

Bender JD, Pommert L, Backus LR, Bidwell A, Blank C, Breese EH, et al. CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70268

BibTeX
@article{Bender2026,
  author = {Bender, Jonathan D and Pommert, Lauren and Backus, Lori R and Bidwell, Andrea and Blank, Courtney and Breese, Erin H and Burns, Karen C and Lane, Adam and Lee, Lynn H and Mizukawa, Benjamin and Norris, Robin E and O'Brien, Maureen M and Peck, Daniel and Phillips, Christine and Ryan, Thomas D and Young, Jennifer and Absalon, Michael and Perentesis, John P},
  title = {CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70268}
}
Kostenlos starten →